Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free EFTRW Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

eFFECTOR Therapeutics (EFTRW) Competitors

eFFECTOR Therapeutics logo
Compare

EFTRW vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

Should you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

How does eFFECTOR Therapeutics compare to Ainos?

eFFECTOR Therapeutics (NASDAQ:EFTRW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/AN/AN/AN/A
Ainos$124.16KN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Ainos N/A N/A N/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Ainos'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Ainos Neutral

Summary

Ainos beats eFFECTOR Therapeutics on 1 of the 1 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and eFFECTOR Therapeutics (NASDAQ:EFTRW) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$586.32MN/AN/AN/AN/A
eFFECTOR TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

In the previous week, Alvotech's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Alvotech Neutral
eFFECTOR Therapeutics Neutral

Summary

Alvotech beats eFFECTOR Therapeutics on 1 of the 1 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Aravive?

Aravive (NASDAQ:ARAV) and eFFECTOR Therapeutics (NASDAQ:EFTRW) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
eFFECTOR TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Aravive's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Aravive Neutral
eFFECTOR Therapeutics Neutral

Summary

Aravive beats eFFECTOR Therapeutics on 2 of the 2 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and eFFECTOR Therapeutics (NASDAQ:EFTRW) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
eFFECTOR TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

In the previous week, Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
eFFECTOR Therapeutics Neutral

Summary

Atlantic Coastal Acquisition Corp. II and eFFECTOR Therapeutics tied by winning 0 of the 0 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and eFFECTOR Therapeutics (NASDAQ:EFTRW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Avidity Biosciences currently has a consensus target price of $69.42, suggesting a potential upside of 437.73%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Avidity Biosciences is more favorable than eFFECTOR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32
eFFECTOR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

eFFECTOR Therapeutics has lower revenue, but higher earnings than Avidity Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avidity Biosciences$18.62MN/A-$322.30MN/AN/A
eFFECTOR TherapeuticsN/AN/AN/AN/AN/A

eFFECTOR Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. eFFECTOR Therapeutics' return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Avidity Biosciences-3,650.39% -44.92% -39.57%
eFFECTOR Therapeutics N/A N/A N/A

In the previous week, Avidity Biosciences had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for Avidity Biosciences and 0 mentions for eFFECTOR Therapeutics. Avidity Biosciences' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Avidity Biosciences Neutral
eFFECTOR Therapeutics Neutral

Summary

Avidity Biosciences beats eFFECTOR Therapeutics on 6 of the 9 factors compared between the two stocks.

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTRW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EFTRW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EFTRW vs. The Competition

Export
MetriceFFECTOR TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$451.91M$6.25B$11.77B
Dividend YieldN/A3.86%2.74%5.26%
P/E RatioN/A4.1429.2527.07
Price / SalesN/A6,879.71504.6873.47
Price / CashN/A13.1343.3053.90
Price / BookN/A77.749.676.69
Net IncomeN/A-$96.07M$3.55B$332.64M

eFFECTOR Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EFTRW
eFFECTOR Therapeutics
N/AN/AN/AN/A$0.00N/AN/A10
AIMDW
Ainos
N/A$0.08
+3.3%		N/AN/A$0.00$124.16KN/A40
ALVOW
Alvotech
N/A$0.21
-14.2%		N/AN/A$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EFTRW) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel